Contact
Search

A strong connection: DTMD University and PFÜTZNER Science & Health Institute

One of the greatest medical challenges of our time

Diabetes mellitus is a global pandemic and is one of the greatest medical challenges of the 21st century. The number of people affected worldwide is currently estimated at around 680 million. With the number of cases increasing by a good 10% every year, universities and the pharmaceutical industry are forced to search internationally for new options to sustainably improve diagnostics and therapy through the use of APPs and internet-based services.

Since 2017, PSHI has been the branch of the affiliated Institute of Internal Medicine and Laboratory Medicine of the University for Digital Technologies in Medicine and Dentistry, Wiltz, Luxembourg

To DTMD University

A strong connection together

Against this background, the DTMD University for Digital Technologies in Medicine & Dentistry (DTMD University), based in Wiltz Castle, Luxembourg, and the PFÜTZNER Science & Health Institute from Mainz, Germany (PSHI), have founded a joint affiliated institute at DTMD University (Institute for Internal Medicine and Laboratory Medicine, IML).

Prof. André Reuter, President of DTMD University, commented: “The new institute will expand the range of courses and research resources at DTMD University to include important fields of human medicine. The existing network of the PSHI with the American Diabetes Treatment Centers International Group based in New York, USA, will also contribute to the sustainable expansion and optimization of the international spectrum of our university”.

"

In the near future, our joint affiliated institute will participate in DTMD University's part-time postgraduate master's programmes with specific courses and projects on digitalization in the diagnosis and treatment of chronic diseases.

Internationally recognized expert

Prof. Dr. Dr. med. Andreas Pfützner, physician and chemist, has been conducting research in the fields of diabetology, metabolic and cardiovascular diseases for over 25 years. With more than 800 published manuscripts, abstracts and book articles, he is an internationally recognized expert in this field.

Together with his specially trained practice team, he conducts clinical studies at his institute in Mainz, focusing on diabetes technology and new technologies for the diagnosis and monitoring of cardiovascular diseases. As the European headquarters of the “Diabetes Treatment Centers International” group, Prof. Pfützner’s institute in Mainz also plays a leading role in testing new therapy regimes for the treatment of diabetes mellitus and its secondary diseases.

As part of his academic activities as holder of the Chair of Clinical Research at the Technical University of Applied Sciences, Bingen, Germany, Prof. Pfützner introduces students there to the complex field of clinical research on humans. In the future, as Professor of Internal Medicine and Laboratory Medicine at DTMD University, he will also integrate focused modules into the university’s part-time postgraduate Master’s programs. Prof. Dr. Ralf Rössler, Dean at DTMD University, comments: “I am delighted that we are able to expand our faculty with Andreas Pfützner, an internationally renowned physician, teacher and researcher, who will offer DTMD University and its students new options with the newly founded Institute of Internal Medicine and Laboratory Medicine.”

GCP seminars at the sciema Academy

The course content is currently under development.

If you are interested, please send us a message to

Write a message

List of publications of the IML (Institute of Internal Medicine and Laboratory Medicine)

Prof. Andreas Pfützner, MD, PhD

  1. Pfützner A.: Patient preference for insulin injection devices. Analysis of the article by Pohlmeier et al. J. Diabetes Sci. Technol. 11 (2017) 270-271
  2. Pfützner A., Pfützner A.H., Kann P.H., Burgard G.: Clinical and Laboratory Evaluation of a New Specific Point of Care Test for Intact Proinsulin. J. Diabetes Sci. Technol. 11 (2017) 278-283
  3. Kann H.P., Moll R., Bartsch D., Pfützner A., Forst T., Tamagno G., Goebel J.N., Fourkiotis V., Raluca Bergmann S., Collienne M.: Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNA) in insulinomas: Indications and clinical relevance in a single investigator cohort of 47 patients. Endocrine 56 (2017) 158 – 163
  4. Pfützner A., Pesach G., Nagar R.: Technology-derived Storage Solutions for Stabilizing Insulin in Extreme Weather Conditions I: The ViviCap-1 Device. Exp Opin Med Dev. 14 (2017) 709-714.
  5. Pfützner A., Klonoff D., Heinemann L., Ejskjaer N., Pickup J.: Euglycemic Ketosis in Patients with Type 2 Diabetes on SGLT2-Inhibitor Therapy – An Emerging Problem and Solutions Offered by Diabetes Technology. Endocrine 56 (2017) 212 – 216
  6. Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC; SPIRE Cardiovascular Outcome Investigators. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. N Engl J Med. 376 (2017) 1527-1539
  7. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 377 (2017) 644-657.
  8. Wilton P., Steidel M., Krczal G., Hermann I., Pfützner A., Konnerth A., Boonrod K.: Identification of highly specific scFvs against total adiponectin for diagnostic and therapeutic purposes. Biology (Basel). 6 (2017) pii: E26.
  9. Pfützner A. Demircik F., Sachsenheimer D., Spatz J., Pfützner AH, Ramljak S.: Impact of Xylose on Glucose-dehydrogenase-based Blood Glucose Meters for Patient Self-testing. J. Diabetes Sci. Technol. 11 (2017) 577-583
  10. Holman R.R., Bethel M.A., Mentz R.J., Thompson V.P., Lokhnygina Y., Buse J.B., Chan J.C., Choi J., Gustavson S.M., Iqbal N., Maggioni A.P., Marso S.P., Öhman P., Pagidipati N.J., Poulter N., Ramachandran A., Zinman B, Hernandez A.F.; EXSCEL Study Group. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 377 (2017) 1228-1239
  11. Peters A.S., Backhaus J., Pfützner A., Raster M., Burgard G., Demirel S., Böckler D., Hakimi M.: Serum-infrared spectroscopy is suitable for diagnosis of atherosclerosis and ist clinical manifestations. Vibrational Spectroscopy 92 (2017) 20-26
  12. Pfützner A., Nagar R.: ViViCap1: Eine technologische Lösung zur Verbesserung der Stabilität von Insulin bei Verwendung unter extremen Wetterbedingungen Diabetes Stoffw. Herz 26 (2017) 209-215
  13. Pfützner A., Schipper D., Pansky A., Kleinfeld C., Rooitzheim B., Tobiasch E.: Mesenchymal Stem Cell Differentiation into Adipocytes is Equally Induced by Insulin and Proinsulin in vitro. Int. J. Stem Cell 10 (2017) 154-159
  1. Pfützner A., Strobl S., Demircik F., Redert L., Pfützner J., Pfützner A.H., Lier A.: Evaluation of a New Non-invasive Glucose Monitoring Device by Means of Standardized Meal Experiments. J. Diabetes Sci. Technol. 12 (2018) 1178-1183
  2. Pfützner A., Sachsenheimer D., Lier A.: Erhöhtes Proinsulin als früher Hinweis auf einen zukünftigen Typ 2 Diabetes. Diabetes Stoffw. Herz. 27 (2018) 69-73
  3. Feltgen N., Khoramnia R., Koch F., Ulbig M., Hammes H.-P., Strobl S., Pfützner A.: Antiinflammatorisch vs. antihormonell beim diabetischen Makulaödem: Umdenken? Diabetes Stoffw. Herz 27 (2018) 75-84
  4. Pfützner A., Reeh W., Strobl S., Rose D.: Die ViViCap – ein zuverlässiger, wiederverwendbarer Schutz gegen den Abbau von Insulin bei hohen und tiefen Umgebungstemperaturen. Diabetes Stoffw. Herz 27 (2018) 307-311
  1. Pfützner A., Ramljak S., Frisvold R., Birkeland K.: Development of a Novel Osmotic-Pressure-based implantable glucose sensor technology for long-term use in patients with diabetes. Best Practice (Norway) Jun (2018) 33-35
  1. Demircik F., Kirsch V., Ramljak S., Hoff M., Pfützner A.H., Pfützner A. Laboratory Evaluation of Linearity, Repeatability, and Hematocrit Interference with an Internet-enabled Blood Glucose Meter. J. Diabetes Sci. Technol. 13 (2019) 514-521
  2. Pfützner A., Demircik F., KirschV, Pfützner J., Strobl S., Hanna M., Spatz J., Pfützner A.H. System Accuracy Assessment of a Blood Glucose Meter with Wireless Internet Access Associated with Unusual Hypoglycemia Patterns in Clinical Trials J. Diabetes Sci. Technol. 13 (2019) 507-513
  3. Bergenstal R.M., Peyrot M., Dreon D.M., Aroda V.R., Bailey T.S., Brazg R.L., Frias J.P., Johnson M.L., Klonoff D.C., Kruger D.F., Ramtoola S., Rosenstock J., Serusclat P., Weinstock R.S., Naik R.G., Shearer D.M., Zraick V., Levy B.L.; Calibra Study Group. Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. Diabetes Technol Ther. 21 (2019) 273 – 285.
  4. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 394 (2019) 131-138
  5. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 394 (2019) 121-130
  6. Pfützner A., Sachsenheimer D., Hanna M.R., Lier A., Pfützner A.H.: Evaluation of the Non-Invasive Glucose Monitoring Device egm1000TM in Patients with Type 2 Diabetes and Subjects with Prediabetes. J. Diabetes Metab Manag, (2019) JDMM-1000005
  7. Pfützner A., Rose D.: Erfolgreiches personalisiertes Typ 2 Diabetes Management bei Berufspiloten durch ß-Zellschonende De-Eskalationstherapie (DET) – Hintergrund und Fallbeispiele. Diabetes Stoff. Herz 28 (2019) 181-186
  8. Pfützner A., Strobl S., Sachsenheimer D., Lier A., Ramljak S., Demircik F.: Evaluation of the Non-Invasive Glucose Monitoring Device GlucoTrack® in Patients with Type 2 Diabetes and Subjects with Prediabetes. J Diabetes Treat 1 (2019) 1070
  9. Weissenbacher S., Yang C.Y., Kuan T.C., Demircik F., Hanna M., Pfützner A. System Accuracy Assessments with a Blood Glucose Meter with Combined Glucose and ß-Hydroxybutyrate Measurement Capabilities. Exp. Rev. Mol. Diagn. 19 (2019) 1043-1048
  10. Strobl S., Sachsenheimer D., Lier A., Ramljak S., Demircik F., Pfützner A.: Calibration of the Non-Invasive Glucose Monitoring Device GlucoTrack® can be Performed by Means of Different Invasive Glucose Monitoring Methods without Loss of Device Performance EC Endocrinol. Metab. Res. 4(9) (2019) 23-30
  11. Bakris G.L., Agarwal R., Anker S.D., Pitt B., Ruilope L.M., Nowack C., Kolkhof P., Ferreira A.C., Schloemer P., Filippatos G.; on behalf of the FIDELIO-DKD study investigators; FIDELIO-DKD study investigators. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J. Nephrol. 50 (2019) 333-344
  12. Ruilope L.M., Agarwal R., Anker S.D., Bakris G.L., Filippatos G., Nowack C., Kolkhof P., Joseph A., Mentenich N., Pitt B.; FIGARO-DKD study investigators. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Am J. Nephrol. 50 (2019) 345-356
  1. Pfützner A., Demircik F., Pfützner J., Kessler K., Strobl S., Spatz J., Pfützner A.H., Lier A. System Accuracy Assessment of a Combined Invasive and Non-invasive Glucometer. J. Diabetes Sci. Technol. 14 (2020) 575-581.
  2. Han J., Heinemann L., Ginsberg B.H., Alva S., Appel M., Bess S., Chen K.Y., Freckmann G., Harris D.R., Hartwig M., Hinzmann R., Kerr D., Krouwer J., Morrow L., Nichols J., Pfützner A., Pleus S., Rice M., Sacks D.B., Schlueter K., Vesper H.W., Klonoff D.C. The YSI 2300 Analyzer Replacement Meeting Report. J. Diabetes Sci. Technol. 14 (2020) 679-686.
  3. Pfützner A., Manessis A., Hanna M.R., Lewin J.: Increased Intact Proinsulin in the Oral Glucose Challenge Sample is an Early Indicator for Future Type 2 Diabetes Development – Case Reports and Evidence from the Literature. Clin. Lab. 66 (2020) 923-92
  4. Pfützner A., Lazzara M., Jantz J.: Why do people with diabetes have a high risk for severe COVID-19 disease? – A dental hypothesis and possible prevention strategy. J. Diabetes Sci. Technol. 14 (2020) 769-771
  5. Pfützner A., Sorsa T., Nwhator S.O., Räisänen I.T., Sakellari D., Kunde J., Kleine-Gunk B., Frankenberger R.: Warum sind Diabetiker durch das Coronavirus (CoV-2) besonders gefährdet – Möglichkeiten für die orale Diagnostik und bedarfsgerechte Prävention für Patienten und Fachärzte. ZMK 36 (2020) 350-355
  6. Pfützner A., Wilke I.: Comment to Döhla et al., Rapid point-of-care testing for SARS-CoV-2 in a community screening setting shows low sensitivity. Public Health (2020) S003-3506(20)30210-9; doi: 10.1016/j.puhe.2020.05.048
  7. Demircik F., Pfützner J., Kessler K., Strobl S., Redert L., Pfützner A.H., Lier A., Pfützner A.: Performance Evaluation of a New Non-Invasive Glucose Monitoring Device in Different Patient Subtypes During Standardized Meal Experiments, Diabetes Stoffw. Herz 29 (2020) 149 – 155
  8. Hanna M.R., Manessis A., Sachsenheimer D., AlTaweel M., Andor Y., Do L., Pfützner A.: Pulsatile Insulintherapie – Hintergrund und Fallbeispiele. Diabetes Stoffw. Herz 29 (2020) 209-216
  9. Pfützner A., Sorsa T., Nwhator S.O., Räisanen L.T., Sakellari D., Kunde J., Kleine-Gunk B., Frankenberger R.: Warum haben Menschen mit Diabetes ein höheres Risiko für schwere Verläufe einer SARS-CoV-2-Infektion – und was könnte dies mit oraler Hygiene zu tun haben? Diabetes Stoffw. Herz 29 (2020) 234 – 238
  10. Frankenberger R., Pfützner A.: Orale Immunkompetenz in der Corona-Pandemie vs. Systemrelevanz der Zahnmedizin. Gesundh. Ökon Qual Manag 25 (2020) 1-8
  11. Pfützner A., Frankenberger R.: Patienten mit Diabetes haben ein höheres Risiko für schwere Koronaverläufe – welche Schutzmaßnahmen sind möglich? Diabetes Stoffw. Herz 29 (2020) 367-371
  12. Bakris G.L., Agarwal R., Anker S.D., Pitt B., Ruilope L.M., Rossing P., Kolkhof P., Nowack C., Schloemer P., Joseph A., Filippatos G.; FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 383 (2020):2219-2229
  1. Pfützner A., Sachsenheimer D., Pfützner A.H., Demircik F., Forst T.: Impact of Short-Acting Insulin Analogs on Biomarkers of Oxidative Stress and Chronic Systemic Inflammation in Patients with Type 2 Diabetes – Results from a Pilot Study for Hypothesis Generation. Diab. Res. Clin. Pract. EC Endocrinology and Metabolic Research 6.1 (2021): 10-17
  2. Pfützner A., Drexel H., Grafinger P, Hoppichler F., Ludvik B., Prager R., Wascher T.C., Schnell O., Weitgasser R. Impact of a Cinnamon Extract vs. Placebo on Metabolic Control in Patients with Type 2 Diabetes mellitus. EC Endocrinology and Metabolic Research 6.2 (2021): 32-42
  3. Manessis A., Hanna M.R., Sachsenheimer D., Do L., Lewin J.C., Steiner S.S., McCormack S., Demircik F., Pfützner A.: Pulsatile Insulin Infusion as a Treatment Option for Patients with Type 2 Diabetes and Stage III Kidney Failure – Results from a Pilot Study. EC Endocrinology and Metabolic Research 6.4 (2021): 49-54
  4. Pfützner A. Stellenwert der Grippeimmpfung bei Diabetes mellitus in Zeiten von Corona. Diabetes Stoffw. Herz 30 (2021) 329-335
  5. Pfützner A., Sachsenheimer D., Burgard G. Possible Role of Intravenous Hyaluronidase Treatment in Coronary Lesion and Hypertension. J. Case Rep. 11 (2021):160-163
  6. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 385 (2021) 2252-2263.
  1. Nguyen KT, Xu NY, Zhang JY, Heinemann L, Krisiunas EP, Stumpe T, Seid DA, Bonilla R, Bouret L, Burkot W, DuBord AY, Gold K, Pfützner A, Shang T, Klonoff DC. The Diabetes Technology Society Green Declaration. J Diabetes Sci Technol. 16 (2022) 215-217
  2. Gupta S, Saarikko M, Pfützner A, Räisänen IT, Sorsa T. Compromised periodontal status could increase mortality for patients with COVID-19. Lancet Infect Dis. 22 (2022) 314. doi: 10.1016/S1473-3099(22)00065-2.
  3. Manessis A., Hanna M.R., Sachsenheimer D., Lewin J.C., Demircik F., Pfützner A.: Die Pulsatile Insulin Infusionstherapie: Behandlungsoption zur Verzögerung der Dialyse bei Patienten mit Typ-2-Diabetes und Niereninsuffizienz im Stadium III. Diabetes Stoffw. Herz. 31 (2022) 9-13
  4. Gupta S., Mohindra R., Singla M., Khera S., Kumar A., Rathnayake N., Sorsa T., Pfützner A., Räisanen I.T., Soni R.K., Kanta P., Jain A., Gauba K., Goyal K., Singh M.P., Ghosh A., Kajal K., Mahajan V., Suri V., Bhalla A.: Validation of a noninvasive aMMP-8 point-of-care diagnostic methodology in COVID-19 patients with periodontal disease. Clin. Exp. Dent. Res., (2022) 1-14 DOI: 10.1002/cre2.589
  5. Pfützner A., Hanna M.R., Andor Y., Sachsenheimer D., Demircik F., Wittig T., DeFaire J.: Chronic Uptake of A Probiotic Nutritional Supplement (AB001) Inhibits Absorption of Ethylalcohol in the Intestine Tract – Results from a Randomized Double-blind Crossover Study 15 (2022) 11786388221108919
  6. Pfützner A., Kalasauske D., Thomé N.: Blood Glucose Measurement by Means of Glucoseoxidase-based Blood Glucose Test Strips – Clinical Relevance of Laboratory Concerns. Diabetes Stoffw. Herz 31 (2022) 285-288
  7. Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, McGill JB, Rosas SE, Joseph A, Gebel M, Roberts L, Scheerer MF, Bakris GL, Agarwal R; FIDELIO-DKD and FIGARO-DKD Investigators. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Diabetes Care. 45 (2022) 2991-2998
  8. Pfützner A, Schaedlich M. Möller P., Gupta S., Pätilä T., Räisänen I.T., Sorsa T.A. The Oral-Systemic Link: A Review about the strong Correlation between Diabetes mellitus, Periodontitis and COVID-19 Outcome, Med. Res. Arch. 11 (2022) https://doi.org/10.18103/mra.
  1. Pfützner A, Pfützner A, Hanna M, Demircik F, Sachsenheimer D, Wittig T, DeFaire J. Impact of a Single Dose of a Probiotic Nutritional Supplement (AB001) on Absorption of Ethylalcohol: Results From a Randomized Double-Blind Crossover Study. Nutr Metab Insights. 16 (2023) 11786388221141174. doi: 10.1177/11786388221141174.
  2. Pfützner A., Segiet T., Hanna M., Kalasauske D., Sachsenheimer D.: Treatment of Diabetic Foot Syndrome by Means of Hyaluronidase Infusion Therapy – A single case patient report. Med. Clin. Case Rep. (2023) 1-4, https://www.scivisionpub.com/index, DOI: 10.33425/2768-6647.1031
  3. Pfützner A., Sachsenheimer D., Hanna M., Kalasauske D.: Probiotische Keime und Nahrungsergänzungsmittel zur Begleittherapie bei alkoholischer Lebererkrankung. Diabetes Stoffw. Herz 32 (2023) 82-88
  4. Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, Thompson PD, Libby P, Cho L, Plutzky J, Bays HE, Moriarty PM, Menon V, Grobbee DE, Louie MJ, Chen CF, Li N, Bloedon L, Robinson P, Horner M, Sasiela WJ, McCluskey J, Davey D, Fajardo-Campos P, Petrovic P, Fedacko J, Zmuda W, Lukyanov Y, Nicholls SJ; CLEAR Outcomes Investigators Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 388 (2023) 1353-1364.
  5. Pfützner A., Willershausen B., Ernst C.P., Sebus A.: Der Oral-Systemische Link–Ein Überblick über die starke Korrelation zwischen Diabetes mellitus, Parodontitis und COVID-19 Outcome. Diabetes Stoff. Herz 32 (2023) 121-127
  6. Pfützner A., Tencer B., Stamm B., Mehtha M., Sharma P., Gilyazev R., Jensch H., Thomé N., Huth M.: Miniaturization of an Osmotic-Pressure Based Glucose Sensor for Continuous i.p. and s.c. Glucose Monitoring by Means of Nanotechnology Sensors (accepted, in press)
  7. Pfützner A., Segiet T., Hanna M., Kalasauske D., Sachsenheimer D.: Fallbericht: Erfolgreiche Behandlung eines diabetischen Fußsyndroms mit Hyaluronidase-Infusionstherapie Diabetes Stoffw. Herz 32 (2023) 241-244
  8. Rossing P, Burgess E, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Gillard P, MacIsaac RJ, Wainstein J, Joseph A, Brinker M, Roessig L, Scott C, Bakris GL; FIDELIO-DKD Investigators. Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888-897. Diabetes Care. 2023 Sep 1;46(9):1721. doi: 10.2337/dc23-er09. Erratum for: Diabetes Care. 2022 Apr 1;45(4):888-897.
  9. Katehis I., Patruno M., Pfützner A., Manessis A.: A Review of Diabetes Technology During Pregnancy in Women with Pregestational Diabetes Mellitus”. EC Gynaecology 12.10 (2023): 01-15.
  10. Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis. Ann Intern Med. 2023 Dec;176(12):1606-1616.
  11. Pfützner A.: Glukosekosmetik“ vs. Personalisierte Diabetestherapie Teil 1: Funktionelle Phänotypisierung als Grundlage einer individuellen Typ 2 Diabetes Therapie. Diabetes Stoffw. Herz 32 (2023) 299-306
  1. Pfützner A.: „Glukosekosmetik“ vs. personalisierte Diabetestherapie Teil 2: Personalisierte Therapie (Standard of Care plus). Diabetes Stoffw. Herz 33 (2024) 11-19
  2. Pfützner A., Jensch H., Cardinal C., Srikanthamoorthy G., Riehn E., Thome N.: Laboratory protocol and pilot results for dynamic interference testing of continuous glucose monitoring sensors. J. Diabetes Sci. Technol. 18 (2024) 59-65

    — submitted —
  3. Gutting T., Pfützner A.: The Crucial Role of Fecal Management Systems in Intensive Care. Exp. Rev. Med. Devices (submitted)
  4. Gutting T., Brobeil A. Strach L., Stricker E., Boxberger M., Trierweiler-Hauke B., Heine C., Michl P., Luntz S., Robert B., Göbel F., Pfützner A.: Sealing Efficiency and Safety of a Polyurethane-based Fecal Management System in Intensive Care – Results from a Real-World Study
  5. Pfützner A., Rose D.M.: Successful Personalized Type 2 Diabetes Management for Airline Pilots by Means of ß-Cell-protective De-Escalation Treatment (DET) – Background and Case Reports. Clinical Medical Insights: Endocrinology Diabetes (submitted)
  6. Pfützner A., Schädlich M., Gieselmann D.R., Kalasauske D., Hanna M.R., Sachsenheimer D., Kuhl C., Thomé N., Sorsa T.: Clinical and Laboratory Evaluation of a Chairside Test for Assessment of Active Matrix-Metalloproteinase-8 in Saliva. Biomedicines (submitted)
  7. Thomé N., Jensch H., Srikanthamoorthy G., Knörr L., Weingärtner L., Grady M., Setford S., Holt E., Pfützner A.: Dynamic Interference Testing Results with the Dexcom G6 Continuous Glucose Monitoring Device. Diabetes Care (submitted)
  1. Grunberger G., Danne T., Maahs D., Hughes L., Parkin C., Pfützner A.: We Don’t Know What We Don’t Know – CGM Systems and Potentially Interfering Substances. J. Diabetes Sci. Technol. (submitted).